Hematologic Malignancies

Fostamatinib Appears Effective for Immune Thrombocytopenia

Fostamatinib Appears Effective for Immune Thrombocytopenia

Researchers found that stable responses occurred in 18 percent of patients on fostamatinib, versus 2 percent on placebo.

Pre-HSCT Conditioning May Improve Physical Functioning in Hematologic Cancers

Pre-HSCT Conditioning May Improve Physical Functioning in Hematologic Cancers

By

In this retrospective study, researchers assessed the outcomes of 88 patients with hematologic disease who underwent HSCT.

Bendamustine Plus Obinutuzumab, Venetoclax Shows Therapeutic Potential in CLL

Bendamustine Plus Obinutuzumab, Venetoclax Shows Therapeutic Potential in CLL

By

Findings in an ongoing phase 2 trial demonstrate that a sequential regimen of these agents has significant potential to improve depth of response and outcomes for patients with chronic lymphocytic leukemia.

Nonmyeloablative/Reduced-Intensity Conditioning May Reduce Mucositis in HCT

Nonmyeloablative/Reduced-Intensity Conditioning May Reduce Mucositis in HCT

By

Researchers sought to determine if NMA or reduced-intensity conditioning with busulfan improved severity/duration of oral mucositis compared with myeloablative conditioning in patients with hematologic cancer undergoing HCT.

FDA, EU Approvals Sought for Split Dose Regimen of Daratumumab for Multiple Myeloma

FDA, EU Approvals Sought for Split Dose Regimen of Daratumumab for Multiple Myeloma

By

The manufacturer of daratumumab, a CD38-directed antibody for the treatment of multiple myeloma, has submitted a sBLA and a type II variation to the US FDA and European Medicines Agency, respectively, for approval of a split dosing regimen.

8 Hours of Bedrest May Be Ideal After Intrathecal Chemotherapy in Hematologic Cancers

8 Hours of Bedrest May Be Ideal After Intrathecal Chemotherapy in Hematologic Cancers

By

In an open-label study, researchers sought to determine the optimal amount of bed rest after intrathecal chemotherapy for patients with hematologic cancers.

Long-Term Azithromycin May Increase Risk of Relapse of Blood Cancers After HSCT

Long-Term Azithromycin May Increase Risk of Relapse of Blood Cancers After HSCT

By

US FDA issues a recommendation on use of azithromycin in patients with hematologic malignancies who have undergone HSCT.

Effect of HSCT on HRQOL and Posttraumatic Stress in Young Adult Cancer Survivors

Effect of HSCT on HRQOL and Posttraumatic Stress in Young Adult Cancer Survivors

By

Study sought to determine the health-related QOL and posttraumatic stress symptoms in adolescent and young adult cancer survivors post-HSCT compared with their healthy peers.

Bleeding Disorder Treatments: von Willebrand Disease

Treatment options for von Willebrand Disease (VWD).

Isolated mild/moderate thrombocytopenia may not require intervention

1. In a review of children who presented to a specialist hematology clinic with isolated mild or moderate low platelet counts, though causes were variable, most required no interventions. 2. Pediatric patients with isolated mild or moderate thrombocytopenia may not need specialist referral to hematology in most circumstances. Evidence Rating Level: 2 (Good) Study Rundown: []

Navigating Patients with Hematologic Malignancies

Navigating Patients with Hematologic Malignancies

By

Patients with hematologic cancers often require a combination of inpatient and outpatient care. The oncology nurse navigator is an ideal care provider to help patients manage their care and transitions between care settings, according to a presentation at the 2018 ONA Navigation Summit.

Palliative Issues Inadequately Addressed Among Hospitalized Cancer Patients

Palliative Issues Inadequately Addressed Among Hospitalized Cancer Patients

By

Consultations for palliative care for hospitalized highly symptomatic patients with cancer is low regardless of curability or whether patient has hematologic or solid cancer, a study presented at 2018 ASCO has shown.

Online Program Aims to Assist With Clinical Trial Enrollment for Hematologic Cancers

Online Program Aims to Assist With Clinical Trial Enrollment for Hematologic Cancers

By

A newly developed web site, described in a presentation at the 2018 ONS Annual Congress, aims to help nurses and patients explore clinical trial options for patients with hematologic cancers.

Low Level Laser Therapy May Prevent Oral Mucositis During HSCT Conditioning

Low Level Laser Therapy May Prevent Oral Mucositis During HSCT Conditioning

By

Researchers assessed the effectiveness of low level laser therapy in preventing or minimizing oral mucositis in patients with hematologic cancers preparing to undergo HSCT. Results were presented at the 2018 ONS Annual Congress.

Class Preps Patients With AML for Successful At-Home Symptom Management and Self-Care

Class Preps Patients With AML for Successful At-Home Symptom Management and Self-Care

By

A presentation at 2018 ONS Congress described the success of a class focused on preparing patients and their families to management their care after discharge.

Nurse-led Interventions Improve Quality of Life for Lymphoma Survivors

Nurse-led Interventions Improve Quality of Life for Lymphoma Survivors

Patients with lymphoma were interviewed to determine their evaluation of a program that offered continuing clinical care with a nurse-led intervention in the early months of survivorship.

Management of Relapsed/Refractory Marginal Zone Lymphoma: Focus on Ibrutinib

Management of Relapsed/Refractory Marginal Zone Lymphoma: Focus on Ibrutinib

[Cancer Management and Research] A review of marginal zone lymphomas, a common and varied group of hematologic malignancies, and their treatment, with a focus on the Bruton's tyrosine kinase ibrutinib.

Taste Changes After Hematopoietic Stem Cell Transplant Affect QOL in Blood Cancers

Taste Changes After Hematopoietic Stem Cell Transplant Affect QOL in Blood Cancers

By

Slight changes in taste perceptions are noted in patients undergoing HSCT for hematologic cancers. In this study, researchers sought to determine how these changes affect quality of life and nutritional intake.

Intensified Reduced-Intensity Conditioning May Improve Outcomes in CBT

Intensified Reduced-Intensity Conditioning May Improve Outcomes in CBT

By

Researchers compared survival outcomes of thiotepa-based intensified RIC vs standard RIC among patients undergoing cord-blood transplantation (CBT).

Redefining Prognosis for Hematologic Cancers in Older Adults by Age

Redefining Prognosis for Hematologic Cancers in Older Adults by Age

By

A report on how variations in the effects of geriatric syndromes and aging can affect treatment modality choices and outcomes for the eldest older adults with hematologic cancers.

Outcomes for Elderly With Hematologic Cancers Effected by Cognitive Impairments

Outcomes for Elderly With Hematologic Cancers Effected by Cognitive Impairments

By

Study data suggest that cognitive impairments may be associate with worse survival among patients with hematologic cancer.

FDA Approves Fostamatinib for ITP After Insufficient Response to Previous Treatment

FDA Approves Fostamatinib for ITP After Insufficient Response to Previous Treatment

By

The US FDA granted approval to fostamatinib (Tavalisse), a kinase inhibitor, for the treatment of thrombocytopenia in patients with chronic IPT who have had an insufficient response to a previous treatment.

Elevated Pre-HCT Iron Levels Predictive of Worse Survival Outcomes in AML/MDS

Elevated Pre-HCT Iron Levels Predictive of Worse Survival Outcomes in AML/MDS

By

The ALLIVE trial sought to determine if eLPI levels were predictive of iron-related toxicity and mortality after HCT in patients with AML or MDS.

Patients Identify Critical Elements of Support in Hematologic Cancers

Patients Identify Critical Elements of Support in Hematologic Cancers

By

A cross-sectional study asked patients with hematologic cancers to name the components of care they felt were most crucial to their perception of optimal care.

Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms

Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms

By

Researchers investigated the antileukemic activity of metformin and ruxolitinib alone and in combination in patients with myeloproliferative neoplasms.

Bisphosphonate Therapy Underutilized in Multiple Myeloma Bone Disease Management

Bisphosphonate Therapy Underutilized in Multiple Myeloma Bone Disease Management

By

A retrospective study evaluated timing, frequency, dosing, and other factors related to bisphosphonate therapy in patients with multiple myeloma.

Self-efficacy Measure May Be Used to Drive Interventions Post-SCT in Hematologic Cancers

Self-efficacy Measure May Be Used to Drive Interventions Post-SCT in Hematologic Cancers

By

Researchers present findings of a study assessing the value of SESM evaluations in patients with hematologic cancer prior to undergoing SCT at the NACNS 2018 Annual Conference.

Cardiovascular Disease Risks Greater With ITP, Especially After Splenectomy

Cardiovascular Disease Risks Greater With ITP, Especially After Splenectomy

By

Idiopathic thrombocytopenic purpura (ITP) may be linked to an increased risk of cardiovascular disease, but studies have not been conclusive.

Pomalidomide Plus Dexamethasone Effective in R/R Multiple Myeloma

Pomalidomide Plus Dexamethasone Effective in R/R Multiple Myeloma

By

Researchers report on their findings of a retrospective study that compared pomalidomide plus dexamethasone vs dexamethasone alone in patients with relapsed/refractory multiple myeloma.

ITP Treatment Outcomes Not Improved With Intravenous vs Oral Corticosteroids

ITP Treatment Outcomes Not Improved With Intravenous vs Oral Corticosteroids

By

In this prospective study, researchers sought to compare the effectiveness of IV methylprednisolone vs oral prednisone in hospitalized patients with newly diagnosed ITP.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs